Results of combined and chemoradiation treatment of patients with thoracic esophageal cancer according to the data of the regional cancer center-Reference-Cited by-同舟云学术

Results of combined and chemoradiation treatment of patients with thoracic esophageal cancer according to the data of the regional cancer center

Published:2023-11-15 Issue:5 Volume:22 Page:84-95
ISSN:2312-3168
Container-title:Siberian journal of oncology
language:
Short-container-title:Sib. onkol. ž.

Author:

Toneev E. A.¹^ORCID,Pikin О. V.²^ORCID,Dengina N. V.³^ORCID,Ryabov A. B.⁴^ORCID,Мartynov A. A.³^ORCID,Galchin А. V.³^ORCID,Isaev D. N.⁵^ORCID,Firstov A. A.⁵^ORCID,Prohorov D. D.⁶^ORCID

Affiliation:

1. Regional Clinical Cancer Center; Ulyanovsk State University

2. P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministryof Health of the Russia

3. Regional Clinical Cancer Center

4. P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministryof Health of the Russia; National Medical Research Radiological Centre of the Ministryof Health of the Russia

5. Ulyanovsk State University

6. Samara State Medical University of the Ministry of Health of Russia

Abstract

Background. esophageal cancer (ec) is one of the most aggressive malignancies of the gastrointestinal tract. chemoradiation therapy is the standard of care for locally advanced ec.The purpose of the study was to evaluate the efficacy of chemoradiation therapy given alone and in combination with surgery in patients with thoracic esophageal cancer.Material and Methods. From January 1, 2012 to december 31, 2021, a total of 940 patients with thoracic esophageal cancer were registered in the regional cancer registry, of which 178 patients were selected for concurrent chemoradiotherapy (CRT) at clinical stages I–III. thirty seven thoracic esophageal cancer patients who received CRT and required treatment interruption due to complications were not included in our analysis. The final analysis included 141 patients.Results. 37 (20.7 %) patients were unable to complete treatment due to intolerance and the development of severe complications of CRT. Hematological toxicity of grade 3-4 was noted in 21 patients (14.8 %). Non-hematological complications of grade 2-4 were noted in 109 patients (77.3 %). The 5-year relapse-free survival rates in patients undergoing and non-undergoing to surgery were 23.0 and 25.0 %, respectively (p=0.018). Overall 5-year survival rates were 24 and 27 %, respectively (p=0.020). The rate of pathological complete response (pcR) was 43.5 % (in 20 of 46 patients who underwent surgery after CRT). The median survival time in patients with clinical complete response (ccR) was 24.0 months and the median survival time in patients with pcR was 29.0 months. The 3-year survival rates were 21 and 45 %, respectively (p=0.050).Conclusion. The combination of chemoradiotherapy and surgery in patients with thoracic esophageal cancer demonstrated an increase in overall survival in our study. if there is a complete clinical response to CRT and contraindications for surgery or the patient’s refusal to undergo surgery, it is advisable to use the “wait & watch” tactic.

Publisher

Tomsk Cancer Research Institute

Subject

Cancer Research,Oncology

Reference12 articles.

1. Cancer care for the population of Russia in 2020. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2021. 252 p. (in Russian).

2. Shah M.A., Kennedy E.B., Catenacci D.V., Deighton D.C., Goodman K.A., Malhotra N.K., Willett C., Stiles B., Sharma P., Tang L., Wijnhoven B.P.L., Hofstetter W.L. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38(23): 2677–94. doi: 10.1200/JCO.20.00866. Erratum in: J Clin Oncol. 2020; 38(33): 3976.

3. Kumar T., Pai E., Singh R., Francis N.J., Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol. 2020; 18(1): 59. doi: 10.1186/s12957020-01830-x.

4. Eyck B.M., van Lanschot J.J.B., Hulshof M.C.C.M., van der Wilk B.J., Shapiro J., van Hagen P., van Berge Henegouwen M.I., Wijnhoven B.P.L., van Laarhoven H.W.M., Nieuwenhuijzen G.A.P., Hospers G.A.P., Bonenkamp J.J., Cuesta M.A., Blaisse R.J.B., Busch O.R., Creemers G.M., Punt C.J.A., Plukker J.T.M., Verheul H.M.W., Spillenaar Bilgen E.J., van der Sangen M.J.C., Rozema T., Ten Kate F.J.W., Beukema J.C., Piet A.H.M., van Rij C.M., Reinders J.G., Tilanus H.W., Steyerberg E.W., van der Gaast A.; CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021; 39(18): 1995–2004. doi: 10.1200/jCO.20.03614.

5. Hulshof M.C.C.M., Geijsen E.D., Rozema T., Oppedijk V., Buijsen J., Neelis K.J., Nuyttens J.J.M.E., van der Sangen M.J.C., Jeene P.M., Rein-ders J.G., van Berge Henegouwen M.I., Thano A., van Hooft J.E., van Laarhoven H.W.M., van der Gaast A. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021; 39(25): 2816–24. doi: 10.1200/JCO.20.03697.